MONTREAL, CANADA--(Marketwire - October 24, 2007) - AngioChem is pleased to announce that it has received clearance from the US Food and Drug Administration to move its lead drug candidate, ANG1005, into Phase 1/2 clinical development targeting primary (glioblastoma) and metastatic brain tumors. ANG1005 consists of a proprietary vector that transports drugs across the blood-brain barrier (BBB) conjugated to three molecules of paclitaxel - a well-known anti-cancer drug. AngioChem believes that its vector will allow paclitaxel to extend its treatment potential to forms of cancer that remain virtually untreatable to date.
